Last reviewed · How we verify
GSK1292263
GSK1292263 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
GSK1292263 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Mantle cell lymphoma, Marginal zone lymphoma.
At a glance
| Generic name | GSK1292263 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BTK is a key component of the B cell receptor signaling complex and plays a critical role in the activation of B cells. Inhibiting BTK has been shown to reduce the activity of B cells, which are involved in the development of certain types of cancer.
Approved indications
- Mantle cell lymphoma
- Marginal zone lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin (PHASE2)
- A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PHASE2)
- A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263 (PHASE2)
- A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs. (PHASE1)
- A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |